Literature DB >> 20075703

Reactive hemophagocytic syndrome in adult-onset Still disease: clinical features and long-term outcome: a case-control study of 8 patients.

Arnaud Hot1, Myew-Ling Toh, Brigitte Coppéré, Laurent Perard, Marie Hélène Girard Madoux, Christelle Mausservey, Hélène Desmurs-Clavel, Martine Ffrench, Jacques Ninet.   

Abstract

Reactive hemophagocytic syndrome (RHS) is a rare, life-threatening, and little-known complication of rheumatic diseases. This disorder is characterized by fever, pancytopenia, liver failure, coagulopathy, and neurologic symptoms. RHS may develop in patents who have lymphoma, organ transplantation, serious infection, and rheumatic diseases, most notably systemic lupus erythematosus and adult-onset Still disease (AOSD). Observations of specific cases of RHS in AOSD remain rare, and the significance of this syndrome during the course of AOSD remains unknown. We retrospectively studied 16 episodes of AOSD-associated RHS in 8 patients. To determine whether RHS is associated with a particular phenotype of AOSD, we conducted a case-control study from the cohort of AOSD patients seen during the same period. The estimated frequency of RHS in AOSD patients from our cohort was 15.3% (8/52). The median age at RHS diagnosis was 44.5 years. We collected clinical and laboratory data. RHS was the first manifestation of AOSD in 7 cases. The main symptoms were fever (n = 8), salmon rash (n = 6), arthralgia (n = 7), lymphadenopathy (n = 6), and shock (n = 4). Serum ferritin concentration was consistently elevated (>1000 microg/L in 8 cases), and the level of glycosylated ferritin was low in all cases (<5% in 7 cases, 15% in 1 case). Six patients presented with coagulopathy; hypertriglyceridemia was found in 6 cases. Admission to the intensive care unit was required in 4 cases. Treatment included corticosteroids (n = 8) and intravenous immunoglobulin (n = 6), cyclophosphamide in 2 cases, infliximab in the same 2 cases, and cyclosporine in 1 case. With a follow-up ranging from 2 to 15 years, the patients were in remission with prednisone plus methotrexate (n = 4), prednisone plus infliximab (n = 2), and low-dose prednisone alone (n = 2). We compared the 8 patients included in this study with 44 control patients with AOSD without RHS. Low haptoglobin levels, very high ferritin levels (>10,000 microg/L), and a normal or low neutrophil count seem to be predictive factors of the occurrence of RHS in AOSD.

Entities:  

Mesh:

Year:  2010        PMID: 20075703     DOI: 10.1097/MD.0b013e3181caf100

Source DB:  PubMed          Journal:  Medicine (Baltimore)        ISSN: 0025-7974            Impact factor:   1.889


  32 in total

Review 1.  Macrophage activation syndrome complicating rheumatic diseases in adults: case-based review.

Authors:  Mayan Gilboa; Gil Bornstein; Ilan Ben-Zvi; Chagai Grossman
Journal:  Rheumatol Int       Date:  2019-07-31       Impact factor: 2.631

2.  [Clinical characteristics and treatment outcomes of macrophage activation syndrome in adults: A case series of 67 patients].

Authors:  H H Yao; Y N Wang; X Zhang; J X Zhao; Y Jia; Z Wang; Z G Li
Journal:  Beijing Da Xue Xue Bao Yi Xue Ban       Date:  2019-12-18

3.  Are the 2016 EULAR/ACR/PRINTO classification criteria for macrophage activation syndrome applicable to patients with adult-onset Still's disease?

Authors:  Yoshifumi Tada; Satomi Inokuchi; Akihito Maruyama; Rie Suematsu; Mariko Sakai; Yuri Sadanaga; Nobuyuki Ono; Yojiro Arinobu; Syuichi Koarada
Journal:  Rheumatol Int       Date:  2018-07-26       Impact factor: 2.631

4.  Correlation of serum CX3CL1 level with disease activity in adult-onset Still's disease and significant involvement in hemophagocytic syndrome.

Authors:  Tsuyoshi Kasama; Hidekazu Furuya; Ryo Yanai; Kumiko Ohtsuka; Ryo Takahashi; Nobuyuki Yajima; Yusuke Miwa; Kazuo Kobayashi
Journal:  Clin Rheumatol       Date:  2012-02-10       Impact factor: 2.980

5.  Epidemiological study of adult-onset Still's disease using a Japanese administrative database.

Authors:  Nobuo Sakata; Sayuri Shimizu; Fumio Hirano; Kiyohide Fushimi
Journal:  Rheumatol Int       Date:  2016-08-09       Impact factor: 2.631

6.  Successful treatment of adult-onset still disease caused by pulmonary infection-associated hemophagocytic lymphohistiocytosis: A case report.

Authors:  Gui Wang; Xiao-Rong Jin; De-Xun Jiang
Journal:  World J Clin Cases       Date:  2020-02-06       Impact factor: 1.337

7.  Synergistic defects of UNC13D and AP3B1 leading to adult hemophagocytic lymphohistiocytosis.

Authors:  Lili Gao; Lijun Zhu; Liang Huang; Jianfeng Zhou
Journal:  Int J Hematol       Date:  2015-05-16       Impact factor: 2.319

8.  Reactive hemophagocytic syndrome in adult-onset Still disease: clinical features, predictive factors, and prognosis in 21 patients.

Authors:  Chang-Bum Bae; Ju-Yang Jung; Hyoun-Ah Kim; Chang-Hee Suh
Journal:  Medicine (Baltimore)       Date:  2015-01       Impact factor: 1.889

9.  Association of CXCL10 and CXCL13 levels with disease activity and cutaneous manifestation in active adult-onset Still's disease.

Authors:  Jae Ho Han; Chang-Hee Suh; Ju-Yang Jung; Jin-Young Nam; Jee Eun Kwon; Hyunee Yim; Hyoun-Ah Kim
Journal:  Arthritis Res Ther       Date:  2015-09-19       Impact factor: 5.156

10.  Adult-onset still disease: manifestations, treatment, outcome, and prognostic factors in 57 patients.

Authors:  Mathieu Gerfaud-Valentin; Delphine Maucort-Boulch; Arnaud Hot; Jean Iwaz; Jacques Ninet; Isabelle Durieu; Christiane Broussolle; Pascal Sève
Journal:  Medicine (Baltimore)       Date:  2014-03       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.